Bisphosphonates: A review of their pharmacokinetic properties

Bone

Volumn 18, Issue 2, 1996, Pages 75-85

  Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bisphosphonates; Bone uptake; Calcium dependent protein binding; Paracellular transport

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID;

BONE LEVEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; DRUG URINE LEVEL; FEMALE; GASTROINTESTINAL ABSORPTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; MALE; NONHUMAN; OSTEOLYSIS; PLASMA PROTEIN BINDING; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; URINARY EXCRETION;

EID: 0029886359     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/8756-3282(95)00445-9     Document Type: Review

References (96)

1. Arie ńs, E. J. Excursions in the field of SAR: a consideration of the past, the present and the future. Keverling Buisman, J. A., Ed. Biological activity and chemical structure. Amsterdam: Elsevier; 1977; 1-35.
2. Arie ńs, J. A. and Simonis, A. M. Optimalization of pharmacokinetics - An essential aspect of drug development. Keverling Buisman, J. A., Ed. Strategy in drug research. Amsterdam: Elsevier; 1981; 165-178.
3. Armstrong, W. M. and Garcia-Diaz, J. F. Electrical phenomena and ion transport in the small intestine. Csaky, T. Z., Ed. Handbook of experimental pharmacology. Vol. 70(I). New York: Springer; 1984; 309-380.
4. Aurbach, G. D. Calcium-regulating hormones: parathyroid hormone and calcitonin. Nordin, B. E. C., Ed. Calcium in human biology. New York: Springer; 1988; 43-68.
5. Azuma, Y., Sato, H., Oue, Y., Okabe, K., Ohta, T., Tsuchimoto, M., and Kiyoki, M. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 16:235-245; 1995.
6. Bijvoet, O. L. M., Frijlink, W. B., Jie, K., van der Linden, H., Meijer, C. J. L. M., van Paassen, H. C., Reitsma, P. H., te Velde, J., de Vries, E., and van der Wey, J. P. APD in Paget's disease of bone. Role of mononuclear phagocyte system? Arth Rheum 23:1193-1204; 1980.
7. Boulenc, X., Marti, E., Joyeux. H., Roques, C., Berger, Y., and Fabre, G. Importance of the paracellular pathway for the transport of a new bisphosphate using the human Caco-2 monolayers model. Pharmacol Biochem 46:1591-1600; 1993.
8. Chadwick, V. S., Phillips, S. F., and Hofmann, A. F. Measurements of intestinal permeability using low molecular weight polyethylene glycol (PEG 400) 1. Chemical analysis and biological properties of (PEG 400). Gastroenterology 73:241-246; 1977.
9. Chadwick, V. S., Phillips, S. F., and Hofmann, A. F. Measurements of intestinal permeability using low molecular weight polyethylene glycos (PEG 400). 2. Application to normal and abnormal permeability states in man and animals. Gastroenterology 73:247-251; 1977.
10. Conrad, K. A. and Lee. S. M. Clodronate kinetics and dynamics. Clin Pharmacol Ther 30:114-120; 1981.
11. 14C-labelled APD and 99m Tc-labelled ADP in the mouse. Calcif Tissue Int 43:125-127; 1988.
12. Daley-Yates, P. T., Cal, J. C., Cockshott, A., Pongchaidecha, M., and Gilchrist, K. Plasma protein binding of APD: Role of calcium and transferrin. Chem Biol Interact 81:79-89; 1992.
13. Daley-Yates, P. T., Dodwell, D. J., Pongchaidecha, M., Coleman, R. E., and Howell, A. The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 49:433-435; 1991.
14. Daley-Yates, P. T., Gifford, L. A., and Hoggarth, C. R. Assay of 1-hydroxy-3-aminopropylidene-l,l-bisphosphonate and related bisphosphonates in human urine and plasma by high performance ion chromatography. J Chromatogr 490:329-338; 1989.
15. Eriksen, E. F., Gundersen, H. J. G., Melsen, F., and Mosekilde, L. Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition. Metab Bone Dis Rel Res 5:243-252; 1984.
16. Eriksen, E. F., Mosekilde, L., and Meisen, F. Kinetics of trabecular bone resorption and formation in hypothyroidism: evidence for a positive balance per remodeling cycle. Bone 7:101-108; 1986.
17. Eriksen, E. F., Mosekilde, L., and Melsen, F. Trabecular bone remodeling and bone balance in hyperthyroidism. Bone 6:421-428; 1984.
18. Fitton, A. and McTavish, D. Pamidronate: a review of its pharmacological properties and therapeutic efficiency in resorptive bone disease. Drugs 41:289-318; 1991.
19. Fleisch, H. Bisphosphonates. Mechanism of action and clinical applications. Peck, W. A., Ed. Bone and mineral research. Annual I. Amsterdam: Excerpta Medica; 1983; 319-357.
20. Fleisch, H. Bone and mineral metabolism. Fleisch, H., Ed. Bisphosphonates in bone disease: From the laboratory to the patients. Berne, Switzerland: Stampfli 1993; 8-24.
21. Fleisch, H. and Felix, R. Diphosphonates. Calcif Tissue Int 27:91-94; 1979.
22. Fleisch, H., Russell, R. G. G., Bisaz, S., Casey, P. A., and Mühlbauer, R. C. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res 2(suppl.):10-10A; 1968.
23. Fleisch, H., Russell, R. G. G., and Francis, M. D. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262-1264; 1969.
24. Fleisch, H. and Russell, R. G. G. Pyrophosphate and polyphosphate. In Encyclopaedia (Int.) of pharmacology and therapeutics. Section S1: Pharmacology of the endocrine system and related drugs. New York: Pergamon; 1970; 61-100.
25. Fleisch, H., Russell, R. G. G., and Straumann, F. Effect of pyrophosphonate on hydroxyapatite and its implications in calcium homeostasis. Nature 212:901-903; 1966.
26. Flesch, G. and Hauffe, S. A. Determination of the bisphosphonate pamidronate disodium in urine by pre-column derivatization with fluorescamine, highperformance liquid chromatography and fluorescence detection. J Chromatogr 489:446-451; 1989.
27. Fogelman, I., Smith, L., Mazess, R., Wilson, M. A., and Bevan, J. A. Absorp-tion of oral disphosphonates in normal subjects. Clin Endocrinol 24:57-62; 1986.
28. Gertz, B. J., Holland, S. D., Kline, W. F., Matuszewski, B. K., and Porras, A. G. Clinical pharmacology of alendronate sodium. Osteopor Int 3(suppl. 3):513-516; 1993.
29. Gibaldi, M. and Perrier, D. Absorption kinetics and bioavailability. Gibaldi, M., and Perrier, D., Eds. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982; 145-198.
30. Greven, J. Renal transport of drugs. Renal transport of organic substances. Greger, R., Lang, F., and Silbernagl, S., Eds. New York: Springer; 1981; 1-263.
31. Gural, R. P., Chungi, V. S., Shrewsburg, R. P., and Dittert, L. W. Dose-dependent absorption of disodium etidronate. J Pharm Pharmacol 37:443-445; 1985.
32. Hanhijäri, H., Elomaa, I., Karlsson, M., and Lauren, L. Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days. Int J Clin Pharmacol Ther Toxicol 27:602-606; 1989.
33. Henry, J. A., Dunlop, A. W., Mitchell, S. N., Turner, P., and Adams, P. A model for the pH dependency of drug-protein binding. J Pharm Pharmacol 33:179-182; 1981.
34. Hewitt, W. R. and Hook, J. B. The renal excretion of drugs. Bridges, W. and Chasseaud, L. F., Eds. Progress in Drug Metabolism. Vol. 7. New York: Wiley; 1983; 11-56.
35. Hu, Z. Glucose effects on intestinal drug absorption: contributions of microclimate pH and paracellular pathway. Ph.D. dissertation. Ann Arbor, MI: University of Michigan; 1992.
36. Hyldstrup, L., Flesch, G., and Hauffe, S. A. Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration. Calcif Tissue Int 53:297-300; 1993.
37. Janner, M., Muhlbauer, R. C., and Fleisch, H. Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcif Tissue Int 49:280-283; 1991.
38. Julin, B. G., Vandenborn, H. W., and Kirkland, J. J. Selective flame emission detection of phosphorus and sulfur in high-performance liquid chromatography. J Chromatogr 112:443-453; 1975.
39. Jung, A., Bisaz, S., and Fleisch, H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 11:269-280; 1973.
40. Kahn, A. J., Fallon, M. D., and Teitelbaum, S. L. Structure-function relationships in bone: an examination of events at the cellular level. Peck, W. A., Ed. Bone Miner Res 2. Amsterdam: Elsevier, 1984; 125-174.
41. Kasting, G. B. and Francis, M. D. Retention of etidronate in human, dog and rat. J Bone Miner Res 7:513-522; 1992.
42. Kline, W. F. and Matuszewski, B. K. Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection. J Chromatogr 583:183-193; 1992.
43. Kragh-Hansen, U. and Moller, J. V. Protein binding of small molecules I. Effect of pH and inorganic salts on the combination of phenol red with proteins. Biochem Biophys Acta 295:438-446; 1973.
44. Lauren, L., Osterman, T., and Karhi, T. Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats. Pharmacol Toxicol 69:365-368; 1991.
45. Leyvraz, S., Hess, U., Flesch, G., Bauer, J., Hauffe, S., Ford, J. M., and Burckhardt, P. Pharmacokinetics of pamidronate in patients with bone metastasis. J Nat Cancer Inst 84:788-792; 1992.
46. Lin, J. H., Chen, I-W., and deLuna, F. A. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 20:473-478; 1992.
47. Lin, J. H., Chen, I-W., and deLuna, F. A. On the absorption of alendronate in rats. J Pharm Sci 83:1741-1746; 1994.
48. Lin, J. H., Chen, I-W., deLuna, F. A., and Hichens, M. Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos 20:608-613; 1992.
49. Lin, J. H., Cocchetto, D. M., and Duggan, D. E. Protein binding as a primary determinant of clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokin 12:402-432; 1987.
50. Lin, J. H., Chen, I-W., and deLuna, F. A. Uptake of alendronate by the bone tissues in hypocalcemic and hypercalcemic rats. Drug Metab Dispos 21:800-804; 1993.
51. Lin, J. H., Chen, I-W., deLuna, F. A., and Hichens, M. The role of calcium in plasma protein binding and renal handling of alendronate in hyper- and hypocalcemic rats. J Pharmacol Exp Ther 267:670-675; 1993.
52. Lin, J. H., Chen, I-W., and deLuna, F. A. Nonlinear kinetics of alendronate: plasma protein binding and bone uptake. Drug Metab Dispos 22:400-405; 1994.
53. Lin, J. H., Chen, I-W., and Ulm, E. H. Dose-dependent kinetics of cilastatin in laboratory animals. Drug Metab Dispos 17:426-432; 1989.
54. Lin, J. H., Chen, I-W., Ulm, E. H., and Duggan, D. E. Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. Drug Metab Dispos 16:392-396; 1988.
55. Lin, J. H. Dose-dependent pharmacokinetics: Experimental observation and theoretical consideration. Biopharm Drug Dispos 15:1-31; 1994.
56. Lin, J. H., Duggan, D. E., Chen, I-W., and Ellsworth, R. L. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drag Metab Dispos 19:926-932; 1991.
57. Lin, J. H., Los, L. E., Ulm, E. H., and Duggan, D. E. Kinetic studies on the competition between famotidine and cimetidine: evidence of multiple renal secretory systems for organic cations. Drug Metab Dispos 16:52-56; 1988.
58. Meijer, D. K. F., Neef, C., and Groothuis, G. M. M. Carrier-mediated transport in the handling of drugs by the liver. Breimer, D. D. and Speiser, P., Eds. Topics in pharmaceutical sciences. Elsevier; Amsterdam: 1983; 167-189.
59. Meijer, D. F. K., Mol, W. E. M., Müller, M., and Kurz, G. Carrier-mediated transport in the hepatic distribution and elimination of drags, with special reference to the category of organic cations. J Pharmacokin Biopharm 18:35-70; 1990.
60. Michael, W. R., King, W. R., and Wakim, J. M. Metabolism of disodium ethane-1-hydroxy-1, 1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol Appl Pharmacol 21:503-515; 1972.
61. 14C-clodronate in mice and rats. Pharmacol Toxicol 62:51-53; 1988.
62. Mönkkönen, J., Koponen, H-M., and Yalitalo, P. Comparison of the distribution of three bisphosphonates in mice. Pharmacol Toxicol 65:294-298; 1989.
63. 14C]clodronate (dichloromethylene bisphosphonate) disodium in mice. Toxicol Appl Pharmacol 89:287-292; 1987.
64. Mönkkönen, J. and Yalitalo, P. The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice: The effects of vehicle and the route of administration. Eur J Drug Metab Pharmacokin 15:239-243; 1990.
65. Mönkkönen, J., Urtti, A., Paronen, P., Elo, H. A., and Yalitalo, P. The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro. Drag Metab Dispos 17:690-693; 1989.
66. Nielson, H. E., Melsen, F., and Christensen, M. S. Interrelationships between calcium-phosphorous metabolism, serum parathyroid hormone and bone histomorphometry in non-dialyzed and dialyzed patients with chronic renal failure. Min Electrolyte Metab 4:113-122; 1980.
67. Ostovic, D. and Brenner, G. S. Development of subcutaneous and intramuscular formulations of calcium alendronate salts. Pharm Res (in press).
68. Parfitt, A. M. Bone remodeling: relationship to the amount and structure of bone, and the pathogenesis and prevention of fractures. Riggs, B. L. and Melton, L. J., Ill, Eds. Osteoporosis: Etiology, diagnosis and management. New York: Raven; 1988; 45-93.
69. Pedersen. K. O. Binding of calcium to serum albumin. I. Stoichiometry and intrinsic association constant at physiological pH, ionic strength and temperature. Scand I Clin Lab Invest 28:459-469; 1971.
70. Pedersen, K. O. Binding of calcium to serum albumin. II. Effect of pH via competitive hydrogen and calcium ion binding to the imidazole groups of albumin. Scand J Clin Lab Invest 29:75-83; 1972.
71. Pentikainen, P. J., Elomaa, I., Nurmi, A. K., and Karkkainen, S. Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther Toxicol 27:222-228; 1989.
72. Powell, J, H. and DeMark, B. R. Clinical pharmacokinetics of diphosphonates. Garattini, S., Ed. Bone resorption, metastasis and diphosphonates. New York: Raven; 1983; 41-49.
73. Recker, R. R. and Saville, P. D. Intestinal absorption of disodium ethane-1-hydroxyl-1-diphosphonate (disodium eidronate) using a deconvolution technique. Toxicol Appl Pharmacol 24:580-589; 1973.
74. Reitsma, P. H., Bijvoet, O. L. M., Potokar, M., Van der Wee-Pals, L. J. A., and Van Wijk-Van Lenne, P. Apposition and disposition of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Calcif Tissue Int 35:37-361; 1983.
75. Reitsma, P. H. Differential actions of bisphosphonates on bone resorbing cells and the adjustment of skeletal metabolism. Ph.D. Dissertation. Leiden, the Netherlands: University of Leiden; 1982.
76. Rennick, B. R. Renal tubule transport of organic cations. Am J Physiol 240:F83-F89; 1981.
77. Reynolds, J. J., Minkin, C., Morgan, D. B., Spycher, D., and Fleisch, H. The effect of two disphosphonates on the resorption of mouse calvaria in vitro. Calcif Tissue Res 10:302-313; 1972.
78. Ruifrok, P. G. and MoI, W. E. M. Paracellular transport of inorganic and or-ganic ions across the rat ileum. Biochem Pharmacol 32:637-640; 1983.
79. Sahni, M1, Guenther, H. L., Fleisch, H., Collin, P., and Martin, T. J. Bisphos-phonates act on rat bone résorption through the mediation of osteoblasts. J Clin Invest 91:2004-2011; 1993.
80. Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., and Rodan, G. A. Bisphosphonate action. Alendronate localization in rat bone and effects on ostcoclast ultrastructure. J Clin Invest 88:2095-2105; 1991.
81. Schenk, R., Eggl, P., Fleisch, H., and Rosini, S. Quantitative morphomeiric evaluation of inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342-349; 1986.
82. Schultz, S. G., Frizzell, R. A., and Nellons, H. N. Ion transport by mammalian small intestine. Annu Rev Physiol 36:51-91; 1974.
83. Schuster, V. L. and Seldin, D. W. Renal clearance. Seldin, D.W. and Giebisch, G., Eds. The Kidney: Physiology and pathophysiology. Vol. 1. New York: Raven; 1985; 365-396.
84. Settle, W., Hegeman, S., and Featherstone, R. M. The nature of drug-protein interaction. Brodie, B. B. and Gillette, J. R., Eds. Concepts in biochemical pharmacology. Part I. Handbook of experimental pharmacology. New York: Springer; 1971; 175-186.
85. Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., and Hagan, P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35:87-99; 1983.
86. Siegert, J. J. and Wood, M. B. Blood flow evaluation of vascularized bone transfers in a canine model. J Orthop Res 8:291-296; 1990.
87. Smith, R. L. Excretion of drugs in bile. Brodie, B. B. and Gillette, J. R., Hand-book of experimental pharmacology. Concepts in biochemical pharmacology. Vol. XXVIII. Berlin: Springer; 1971; 354-389.
88. Szabo, Z., and Szabo, G. The effect of fracture and blood loss on the medullary circulation. Magy Traumatol Orthop Helyreallito Sebesz 21:285-292; 1978.
89. Troehler, U., Bonjour, J-P., and Fleisch, H. Renal secretion of diphosphonates in rats. Kidney Int 8:6-13; 1975.
90. Twiss, I. M., DeWater, R., DenHartigh, J., Sparidans, R., Ram-Koopmanschap, W., Brill, H., Wijdeveld, M., and Vermeij, P. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci 83:699-703; 1994.
91. Wiedmer, W. H., Zbinden, A. M., Trechsel, U., and Fleisch, H. Ultrafiltrability and Chromatographie properties of pyrophosphate, l-hydroxyethylidene-1,1-bisphosphonate, and dichloromethylene-bisphosphonate in aqueous buffers and in human plasma. Calcif Tissue Int 35:397-400; 1983.
92. Wilkinson, G. R. Clearance approaches in pharmacology. Pharmacol Rev 39:1-47; 1987.
93. Wilson, C. G. and Washington, N. Overview of epithelial barriers and drug transport. Wilson, C. G. and Washington, N., Eds. Physiological pharmaceutics: biological barriers to drug transport. Chichester: Ellis Horwood, 1989; 11-20.
94. Wilting, J., von der Giesen, W. F., Janssen, L. H. M., Weideman, M. M., Otagiri, M., and Perrin, J. H. The effect of albumin conformation on the binding of warfarin to human serum albumin. J Biol Chem 255:3032-3038; 1980.
95. Wingen, F. and Schmähl, D. Pharmacokinetics of the osteotropic diphospho-nate 3-amino-l-hydroxypropane-l,l-diphosphonic acid in mammals. ArzneimForsch/Drug Res 37:1037-1042; 1987.
96. Yakatan, G. Y., Poynor, W. J., Talbert, R. L., Floyd, B. F., Slough, C. L., Ampulsk, R. S., and Benedict, J. J. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 31:402-410; 1982.